Skip to main
TARA

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc is well-positioned for growth due to its promising interim data from the Phase 2 ADVANCED-2 trial, showcasing TARA-002's efficacy and durability in BCG-naïve patients, which is essential for competing in this market. The potential first-mover advantage in the BCG-naïve setting, combined with proactive FDA engagement for a registrational path, suggests a credible opportunity for Protara to capture significant market share in the near future. Additionally, strong responses and safety profiles observed in both lymphatic malformations and intestinal failure associated liver disease highlight the company's capacity for delivering transformative therapies, reinforcing a favorable outlook for its ongoing developments.

Bears say

Protara Therapeutics has been facing significant challenges related to its ongoing development programs, particularly TARA-002 and IV choline chloride, which could impact timely commercialization and overall revenue generation. The company's financial metrics indicate increasing operational costs without a corresponding rise in revenue, leading to concerns about sustainable cash flow and funding capabilities for its pipeline initiatives. Additionally, potential regulatory hurdles and market competition for its targeted therapies further contribute to a negative outlook regarding the stock's future performance.

TARA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 4 analysts, TARA has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.